Примери за използване на Granted a marketing authorisation на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The European Commission granted a marketing authorisation valid throughout the European Union, for MS-H vaccine on 14 June 2011.
The review also included a centrally-authorised medicine, ellaOne,which contains ulipristal acetate and was granted a marketing authorisation in the EU in 2009.
The European Commission granted a marketing authorisation valid throughout the European Union for Fortekor Plus on 8 September 2015.
Urokinase is considered to have a well-established use in the above indications within the European Union andon 29 September 2006, Syner-Kinase was granted a marketing authorisation in the UK according to Article 10(a) of Directive 2001/83/EC.
The European Commission granted a marketing authorisation valid throughout the EU for Suvaxyn Circo+MH RTU on 6 November 2015.
Any medicinal product not appearing in Annex I may be granted a marketing authorisation by the Union in accordance with this Regulation, if.
The European Commission granted a marketing authorisation valid throughout the European Union, for Poulvac E. coli on 15 June 2012.
Any medicinal product not appearing in the Annex may be granted a marketing authorisation by the Community in accordance with the provisions of this Regulation, if.
The European Commission granted a marketing authorisation valid throughout the European Union, for Fevaxyn Pentofel to Fort Dodge Laboratories Ireland on 5 February 1997.
The European Commission granted a marketing authorisation valid throughout the EU for Advate to Baxter AG on 2 March 2004.
The European Commission granted a marketing authorisation valid throughout the European Union for Nobilis IB 4-91 on 9 June 1998.
The European Commission granted a marketing authorisation valid throughout the European Union, for Eryseng on 4 July 2014.
The European Commission granted a marketing authorisation valid throughout the European Union, for Melovem on 7 July 2009.
The European Commission granted a marketing authorisation valid throughout the EU for Ribavirin Three Rivers on 10 June 2010.
The European Commission granted a marketing authorisation valid throughout the EU for Celvapan to Baxter AG on 04 March 2009.
The European Commission granted a marketing authorisation valid throughout the European Union for ProteqFlu on 6 March 2003.
The European Commission granted a marketing authorisation valid throughout the European Union, for Veraflox to Bayer Animal Health GmbH on 12/04/2011.
The European Commission granted a marketing authorisation valid throughout the European Union for KOGENATE Bayer on 4 August 2000.
The European Commission granted a marketing authorisation valid throughout the EU for Siklos to Addmedica on 29 June 2007.
The European Commission granted a marketing authorisation valid throughout the EU for LITAK to Lipomed GmbH on 14 April 2004.
The European Commission granted a marketing authorisation valid throughout the EU for ZULVAC 8 Ovis on 15 January 2010.
The European Commission granted a marketing authorisation valid throughout the European Union, for Ibraxion to Merial on 9 March 2000.
The European Commission granted a marketing authorisation valid throughout the EU for Binocrit to Sandoz GmbH on 28 August 2007.
The European Commission granted a marketing authorisation valid throughout the EU for Omnitrope to Sandoz GmbH on 12 April 2006.
The European Commission granted a marketing authorisation valid throughout the European Union for Possia to AstraZeneca on 03 December 2010.
The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic acid Mylan on 23 August 2012.
The European Commission granted a marketing authorisation valid throughout the European Union, for Equilis Prequenza on 8 July 2005.
The European Commission granted a marketing authorisation valid throughout the European Union, for CaniLeish to Virbac S.A. on 14/03/2011.
The European Commission granted a marketing authorisation valid throughout the EU for Optaflu to Novartis Vaccines and Diagnostics GmbH& Co.
The European Commission granted a marketing authorisation valid throughout the European Union for ZIMULTI to sanofi-aventis on 19 June 2006.